EHA 2021 | GIMEMA LAL2116 trial and the GIMEMA LAL1509 protocol

Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, discusses the GIMEMA LAL1509 protocol (EudraCT 2010-019119-39) which was designed for adult patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), based on dasatinib plus steroids induction, with CNS prophylaxis, followed by dasatinib monotherapy for patients in complete molecular response, or chemotherapy and/or allogeneic transplantation in patients who did not achieve a complete molecular response. At a median follow-up of 57.4 months, overall survival and disease-free survival were reported at 56.3% and 47.2% respectively. Dr Chiaretti also discusses updated results from the GIMEMA LAL2116 trial (NCT02744768) based on dasatinib plus steroids followed by a minimum of two cycles of blinatumomab and CNS prophylaxis. At a median follow-up of 27.2 months, the 24-month overall survival rate was 87.8% and the disease-free survival (DFS) rate wat 79.8%. Inferior DFS was found to be associated with IKZF1-plus genotype. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.